These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30102705)

  • 1. Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.
    Converse PJ; Almeida DV; Tasneen R; Saini V; Tyagi S; Ammerman NC; Li SY; Anders NM; Rudek MA; Grosset JH; Nuermberger EL
    PLoS Negl Trop Dis; 2018 Aug; 12(8):e0006728. PubMed ID: 30102705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.
    Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
    Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.
    Almeida DV; Omansen TF; Li SY; Lee J; Grosset JH; Converse PJ; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
    Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
    Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antibacterial activity and in vivo efficacy of hydrated clays on Mycobacterium ulcerans growth.
    Adusumilli S; Haydel SE
    BMC Complement Altern Med; 2016 Jan; 16():40. PubMed ID: 26833071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of rifalazil (KRM-1648) in a M. ulcerans-induced Buruli ulcer mouse model.
    Fukano H; Nakanaga K; Goto M; Yoshida M; Ishii N; Hoshino Y
    PLoS One; 2022; 17(10):e0274742. PubMed ID: 36201529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic management of
    Van Der Werf TS; Barogui YT; Converse PJ; Phillips RO; Stienstra Y
    Expert Rev Clin Pharmacol; 2020 Apr; 13(4):391-401. PubMed ID: 32310683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
    Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
    Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should antibiotics be given for Buruli ulcer?
    Johnson PD
    Lancet; 2010 Feb; 375(9715):618-9. PubMed ID: 20137806
    [No Abstract]   [Full Text] [Related]  

  • 11. The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model.
    Liu Y; Gao Y; Liu J; Tan Y; Liu Z; Chhotaray C; Jiang H; Lu Z; Chiwala G; Wang S; Makafe G; Islam MM; Hameed HMA; Cai X; Wang C; Li X; Tan S; Zhang T
    Nat Commun; 2019 Jan; 10(1):524. PubMed ID: 30705268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
    Converse PJ; Nuermberger EL; Almeida DV; Grosset JH
    Future Microbiol; 2011 Oct; 6(10):1185-98. PubMed ID: 22004037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compliance with antimicrobial therapy for buruli ulcer.
    Klis S; Kingma R; Tuah W; Stienstra Y; van der Werf TS
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6340. PubMed ID: 25225342
    [No Abstract]   [Full Text] [Related]  

  • 14. Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.
    Zhang T; Li SY; Converse PJ; Almeida DV; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2011 Jan; 55(1):56-61. PubMed ID: 21078940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Mycobacterium ulcerans cytochrome bc
    Scherr N; Bieri R; Thomas SS; Chauffour A; Kalia NP; Schneide P; Ruf MT; Lamelas A; Manimekalai MSS; Grüber G; Ishii N; Suzuki K; Tanner M; Moraski GC; Miller MJ; Witschel M; Jarlier V; Pluschke G; Pethe K
    Nat Commun; 2018 Dec; 9(1):5370. PubMed ID: 30560872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
    Almeida D; Converse PJ; Ahmad Z; Dooley KE; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2011 Jan; 5(1):e933. PubMed ID: 21245920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reply to "compliance with antimicrobial therapy for buruli ulcer".
    Phillips RO; Sarfo FS; Abass MK; Frimpong M; Ampadu E; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6341. PubMed ID: 25225343
    [No Abstract]   [Full Text] [Related]  

  • 18. Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease.
    Almeida DV; Converse PJ; Li SY; Tyagi S; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2013; 7(2):e2085. PubMed ID: 23469308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Paradoxical reactions and responses during antibiotic treatment for Mycobacterium ulcerans infection (Buruli ulcer). Four cases from French Guiana].
    Sambourg E; Dufour J; Edouard S; Morris A; Mosnier E; Reynaud Y; Sainte-Marie D; Nacher M; Guégan JF; Couppié P
    Ann Dermatol Venereol; 2014; 141(6-7):413-8. PubMed ID: 24951139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.
    Chauffour A; Robert J; Veziris N; Aubry A; Jarlier V
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005066. PubMed ID: 27755552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.